Japanese Pharmaceutical Industry: Recent Perspectives and Areas for Further Research
Japanese Pharmaceutical Industry: Recent Perspectives and Areas for Further Research
复制标题
DOI：
10.21423/jrs-v08shoyo
复制
发表时间：
2020-11
影响因子：
--
通讯作者：
Shoyo Shibata;Koken Ozaki;Takeshi Suzuki
中科院分区：
文献类型：
--
作者：
Shoyo Shibata;Koken Ozaki;Takeshi Suzuki
日本医药市场是世界上最大的医药市场之一。日本政府越来越多地试图控制不断上涨的医疗保健成本，因此，制药公司预计，基于更高水平的创新获得更高价格的机会将会减少；这可能会导致人们对研发 (R&D) 活动的兴趣下降。在此背景下，本文的目的是回顾日本制药行业当前的研发前景，并从监管科学和管理的角度讨论进一步研究的局限性和挑战。鉴于来自日本以外制药行业的监管科学和管理观点的大量证据，以及来自日本国内的有限证据，有必要将日本制药行业的观点与其他国家的观点进行比较，以了解日本制药市场的复杂性以及与提高生产率相关的限制和挑战。 https://doi.org/10.21423/jrs-v08shoyo
The Japanese pharmaceutical market is one of the largest in the world. The Japanese government has increasingly been trying to control rising health care costs, and as a result, pharmaceutical companies are expecting that fewer opportunities will be available to command a higher price based on higher levels of innovation; this will likely lead to decreased interest in research and development (R&D) activities. With this background, the purpose of this article is to review current perspectives for R&D by the Japanese pharmaceutical industry, and to discuss the limitations and challenges for further research from the regulatory science and management perspectives. Given the substantial amount of evidence of regulatory science and management perspectives from the pharmaceutical industry outside of Japan and the limited amount of evidence from inside of Japan, it is important to review perspectives focusing on the Japanese pharmaceutical industry in comparison with those from other countries to understand the complexities of the Japanese pharmaceutical market, as well as the limitations and challenges associated with increasing productivity. https://doi.org/10.21423/jrs-v08shoyo